Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
TOFA
45
CHF
CHF 45.00
In stock
AG-CR1-2905-M0055 mgCHF 45.00
AG-CR1-2905-M02525 mgCHF 190.00
| Product Details | |
|---|---|
| Synonyms | RMI 14514; MDL 14514; 5-(Tetradecyloxy)-2-furoic acid; 5-(Tetradecyloxy)-2-furancarboxylic acid |
| Product Type | Chemical |
| Properties | |
| Formula |
C19H32O4 |
| MW | 324.5 |
| CAS | 54857-86-2 |
| RTECS | LU0288000 |
| Purity Chemicals | ≥98% |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (10mg/ml), DMF (5mg/ml) or ethanol (5mg/ml). |
| InChi Key | CZRCFAOMWRAFIC-UHFFFAOYSA-N |
| Smiles | CCCCCCCCCCCCCCOC1=CC=C(C(O)=O)O1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Fatty acid synthase (FASN) inhibitor.
- Cell permeable, potent, reversible and competitive inhibitor of acetyl-CoA carboxylase (ACC) consequently blocking the synthesis of malonyl-CoA.
- Useful agent for immunometabolism research.
- Anticancer agent. Induces apoptosis in a variety of tumor cell lines. Relatively non-cytotoxic to various cancer cell lines.
- TOFA-induced reduction in malonyl-CoA is reported to off-set the effect of C75 (AG-CR1-2904) on food intake in fasted mice and on apoptosis in tumor cells.
- Hypolipidemic agent.
- Stimulates citrate accumulation in the cell, which leads to a suppression of glycolysis by citrate-induced inhibition of phosphofructokinase.
Product References
- 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids: R.A. Parker, et al.; J. Med. Chem. 20, 781 (1977)
- Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid: D.L. Halvorson & S.A. McCune; Lipids 19, 851 (1984)
- Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines: E.S. Pizer, et al.; Cancer Res. 58, 4611 (1998)
- Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors: T.M. Loftus, et al.; Science 288, 2379 (2000)
- Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity: J.N. Thupari, et al.; BBRC 285, 217 (2001)
- Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells: W. Zhou, et al.; Cancer Res. 63, 7330 (2003)
- C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism: L.E. Landree, et al.; J. Biol. Chem. 279, 3817 (2004)
- TOFA (5-tetradecyl-oxy-2-furoic acid) reduces fatty acid synthesis, inhibits expression of AR, neuropilin-1 and Mcl-1 and kills prostate cancer cells independent of p53 status: N.V. Guseva, et al.; Cancer Biol. Ther. 12, 80 (2011)
- A guide to immunometabolism for immunologists: L.A. O'Neill, et al.; Nat. Rev. Immunol. 16, 553 (2016)
Related Products
